Why the study?
Statin treatment fails to prevent roughly two-thirds of cardiovascular disease onset and progression, highlighting residual risks that may require a multifaceted preventive approach.
Answers are grounded in this paper and cite their sources.
Residual cardiovascular risk after statin therapy is driven by insufficient LDL-C reduction, low HDL-C, elevated triglycerides, and other metabolic factors, highlighting the need for multifaceted and potentially sex-specific preventive strategies.
Major risk factors for cardiovascular disease (CVD) include aging, gender, smoking, family history and cardiometabolic syndrome. The relative residual risks for CVD after statin treatment for primary and secondary prevention have been reported by several large-scale randomized clinical trials. Statin treatment appears to prevent one-third of the onset and progression of CVD, but not the remaining two-thirds. There are three major problems regarding the residual risk of CVD: 1) Insufficient reduction of low-density lipoprotein cholesterol levels; 2) Low levels of high-density lipoprotein cholesterol and elevated triglyceride; and 3) Insufficient control of other risk factors (high blood pressure, obesity, metabolic syndrome, type 2 diabetes, etc.). Thus, a multifaceted preventive approach should be needed to prevent CVD after statin treatment.
No takes yet. Share an insight, caveat, or question.
Miura et al. (2019) conducted a review in Cardiometabolic syndrome and atherosclerotic coronary artery disease. Cardiometabolic risk factors was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: